These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11205153)

  • 1. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.
    Berger T; Reindl M
    J Neural Transm Suppl; 2000; (60):351-60. PubMed ID: 11205153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Stefferl A; Brehm U; Linington C
    J Neural Transm Suppl; 2000; (58):123-33. PubMed ID: 11128602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.
    O'Connor KC; Appel H; Bregoli L; Call ME; Catz I; Chan JA; Moore NH; Warren KG; Wong SJ; Hafler DA; Wucherpfennig KW
    J Immunol; 2005 Aug; 175(3):1974-82. PubMed ID: 16034142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
    Zhou D; Srivastava R; Nessler S; Grummel V; Sommer N; Brück W; Hartung HP; Stadelmann C; Hemmer B
    Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19057-62. PubMed ID: 17142321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
    Reindl M; Linington C; Brehm U; Egg R; Dilitz E; Deisenhammer F; Poewe W; Berger T
    Brain; 1999 Nov; 122 ( Pt 11)():2047-56. PubMed ID: 10545390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
    Lolli F; Rovero P; Chelli M; Papini AM
    Neurology; 2005 Sep; 65(5):781-2; author reply 781-2. PubMed ID: 16157927
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.
    von Büdingen HC; Tanuma N; Villoslada P; Ouallet JC; Hauser SL; Genain CP
    J Clin Immunol; 2001 May; 21(3):155-70. PubMed ID: 11403222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
    Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
    Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis.
    Marta CB; Montano MB; Taylor CM; Taylor AL; Bansal R; Pfeiffer SE
    J Biol Chem; 2005 Mar; 280(10):8985-93. PubMed ID: 15634682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire.
    Mathey E; Breithaupt C; Schubart AS; Linington C
    Eur J Immunol; 2004 Aug; 34(8):2065-71. PubMed ID: 15259003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.
    Marta CB; Oliver AR; Sweet RA; Pfeiffer SE; Ruddle NH
    Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13992-7. PubMed ID: 16172404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogeneity of active demyelinating lesions in established multiple sclerosis.
    Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L
    Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
    Lee DH; Linker RA
    Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
    O'Connor KC; McLaughlin KA; De Jager PL; Chitnis T; Bettelli E; Xu C; Robinson WH; Cherry SV; Bar-Or A; Banwell B; Fukaura H; Fukazawa T; Tenembaum S; Wong SJ; Tavakoli NP; Idrissova Z; Viglietta V; Rostasy K; Pohl D; Dale RC; Freedman M; Steinman L; Buckle GJ; Kuchroo VK; Hafler DA; Wucherpfennig KW
    Nat Med; 2007 Feb; 13(2):211-7. PubMed ID: 17237795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes.
    Kerlero de Rosbo N; Brok HP; Bauer J; Kaye JF; 't Hart BA; Ben-Nun A
    J Neuroimmunol; 2000 Oct; 110(1-2):83-96. PubMed ID: 11024537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).
    Brehm U; Piddlesden SJ; Gardinier MV; Linington C
    J Neuroimmunol; 1999 Jun; 97(1-2):9-15. PubMed ID: 10408984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.
    Haase CG; Schmidt S
    Neurosci Lett; 2001 Jul; 307(2):131-3. PubMed ID: 11427318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis.
    Jégou JF; Chan P; Schouft MT; Griffiths MR; Neal JW; Gasque P; Vaudry H; Fontaine M
    J Immunol; 2007 Mar; 178(5):3323-31. PubMed ID: 17312184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations.
    Pittock SJ; Reindl M; Achenbach S; Berger T; Bruck W; Konig F; Morales Y; Lassmann H; Bryant S; Moore SB; Keegan BM; Lucchinetti CF
    Mult Scler; 2007 Jan; 13(1):7-16. PubMed ID: 17294606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.
    Lalive PH; Menge T; Delarasse C; Della Gaspera B; Pham-Dinh D; Villoslada P; von Büdingen HC; Genain CP
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2280-5. PubMed ID: 16461459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.